Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVENANCE - A Non-interventional Study to Provide Real-world Data on the Use of Avelumab as a Maintenance Treatment for Patients With Advanced or Metastatic Urothelial Carcinoma

Next Previous
X
Search
Trial Profile

AVENANCE - A Non-interventional Study to Provide Real-world Data on the Use of Avelumab as a Maintenance Treatment for Patients With Advanced or Metastatic Urothelial Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary)
  • Indications Carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms AVENANCE
  • Sponsors Pfizer

    • Most Recent Events

    • 27 Jan 2024 Results (At data cutoff (May 31, 2023, n=594) assessing effectiveness of avelumab first-line maintenance in patients with advanced urothelial carcinoma presented at the 2024 Genitourinary Cancers Symposium
    • 23 Jan 2024 According to a Merck & Co media release, data of this study will be presented at the 2024 American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, January 25-27, in San Francisco.
    • 24 Oct 2023 Results of subgroup analysis (n=593; data cutoff March 30, 2023) of avelumab in patients with advanced urothelial carcinoma with histological variants presented at the 48th European Society for Medical Oncology Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top